Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.33 |
| ▸ | FBP1 | P09467 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | LTK | P29376 | 2/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160659 | 0.74 | NTRK1 (0.41) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL743402 | 0.74 | MAPK1 (0.39) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL18671569 | 0.74 | NTRK1 (0.33) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL20271932 | 0.71 | MEN1 (0.36) | CLK4NTRK1LTKTYRO3NTRK2 | |
| Hydrochloric Acid SCHEMBL27786826 | 0.70 | MEN1 (0.35) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL24175622 | 0.69 | NTRK1 (0.34) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL18237486 | 0.69 | ADORA3 (0.37) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL5439409 | 0.69 | CYP2A6 (0.35) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL12343963 | 0.69 | ADORA2A (0.37) | CLK4NTRK1LTKTYRO3NTRK2 | |
| SCHEMBL12341044 | 0.69 | ADORA2A (0.41) | CLK4NTRK1LTKTYRO3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | claimed |
| US-12534451-B2 | Small molecule modulators of PanK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| WO-2025067457-A1 | HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024078372-A1 | HETEROCYCLIC SUBSTITUTED PHENOL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海泽德曼医药科技有限公司 | 2024-04-18 | — | — | WO | disclosed |
| WO-2024048809-A1 | HETEROARYL DERIVATIVE CONTAINING N, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 보로노이 주식회사 | 2024-03-07 | — | — | WO | disclosed |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-07-14 | — | — | US | disclosed |
| US-20220185796-A1 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2022-06-16 | — | — | US | disclosed |
| US-20220185796-A1 | SMALL MOLECULE MODULATORS OF PANK | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2022-06-16 | — | — | US | disclosed |
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006135639-A1 | THIΞNOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES AS FLT-3 KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-6130223-A | Thienopyrimidine with phosphodiesterase V inhibiting effect | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-10-10 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0934321-A1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GmbH (DE) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017668-A1 | THIENOPYRIMIDINE WITH PHOSPHODIESTERASE V INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 1998-04-30 | — | — | WO | disclosed |
| EP-0150469-B1 | THIENO(2,3-D)PYRIMIDINE DERIVATIVES AND SALTS THEREOF | MITSUBISHI KASEI CORPORATION (JP) | 1988-06-15 | — | — | EP | disclosed |
| US-4695568-A | Thieno[2,3-d]pyrimidine derivatives and salts thereof | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1987-09-22 | — | — | US | disclosed |
| EP-0150469-A1 | Thieno(2,3-d)pyrimidine derivatives and salts thereof | MITSUBISHI KASEI CORPORATION (JP) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534451-B2 | Small molecule modulators of PanK | PANK2, PANK1, PANK3 | CLK4 54/4885FBP1 662/4885NTRK1 1279/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | CLK4 3491/4885FBP1 1398/4885NTRK1 4064/4885 |
| US-20220185796-A1 | SMALL MOLECULE MODULATORS OF PANK | PANK2, PANK1, PANK3 | CLK4 494/4885FBP1 575/4885NTRK1 567/4885 |
| US-20220220122-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | CLK4 1346/4885FBP1 1937/4885NTRK1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.